Management of breast cancer patients would clearly be optimized if clinicians had a molecular fingerprint of a patient's tumor at the time of diagnosis that would accurately predict recurrence and treatment response. Therefore, goal of this continuing project is to identify clinically useful biomarkers that will add to existing factors already validated by our group to provide this fingerprint, and to then apply appropriate statistical methodology for their incorporation into indices that can be used in routine patient management. During the present project period we have examined more than 20 potential prognostic markers, including p53, HER-2, S-phase fraction, and our new cell cycle protein mitosin. We have also compared the major factor integration techniques, contributed to the statistical technology for factor evaluation, provided the first demonstration that HER-2 may be associated with CMF resistance, and developed a basic but powerful index for identifying patients at very high risk of recurrence for aggressive adjuvant treatment. To achieve our overall goal, we now propose: (1) To create prognostic indices for patients with primary breast cancer, by: a) using nine commonly available factors to create an index of extremely low recurrence risk, b) validating new proliferation markers including mitosin and Ki67 to replace flow cytometric S-phase in this index, c) expanding this index by including promising newer markers of proliferation, differentiation, and metastatic potential, and D) expanding our index of very high recurrence risk by including additional commonly available factors and promising newer markers; and (2) To evaluate standard and investigational biomarkers for their ability to predict response to adjuvant CMF and to adjuvant tamoxifen, using tissues from two large randomized controlled treatment trails with long clinical follow-up.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA030195-18
Application #
6102072
Study Section
Project Start
1998-08-01
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
18
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Pathiraja, Thushangi N; Nayak, Shweta R; Xi, Yuanxin et al. (2014) Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 6:229ra41
Zhang, Yi; Tseng, Chun-Chih; Tsai, Yuan-Li et al. (2013) Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One 8:e80071
Machado, Heather L; Kittrell, Frances S; Edwards, David et al. (2013) Separation by cell size enriches for mammary stem cell repopulation activity. Stem Cells Transl Med 2:199-203
Zhang, Xiaomei; Claerhout, Sofie; Prat, Aleix et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885-97
Boone, David N; Lee, Adrian V (2012) Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 17:161-73
Casa, Angelo J; Potter, Adam S; Malik, Simeen et al. (2012) Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 132:61-73
Creighton, Chad J (2012) Molecular classification and drug response prediction in cancer. Curr Drug Targets 13:1488-94
Barone, Ines; Brusco, Lauren; Gu, Guowei et al. (2011) Loss of Rho GDI* and resistance to tamoxifen via effects on estrogen receptor *. J Natl Cancer Inst 103:538-52
Rimawi, Mothaffar F; Wiechmann, Lisa S; Wang, Yen-Chao et al. (2011) Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 17:1351-61

Showing the most recent 10 out of 260 publications